Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
573 stopped studies mapped to Multiple Myeloma and descendants · 91% state a reason
Over the 573 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04150692 | Escalation of Daratumumab Frequency Following Biochemical Progression in… | Phase 2 | withdrawn | Nov 5, 2019 | Washington University School of Medicine | Investigator decision | Investigator |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | Phase 1 / Phase 2 | terminated | Sep 20, 2019 | AGC Biologics S.p.A. | Inability to close the study in a clinically relevant time frame | Other (stated, no rule matched) |
| NCT02589860 | Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous… | — | withdrawn | Oct 28, 2015 | Sherif S. Farag | No accrual | Enrollment / accrual |
| NCT04918511 | A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed…(COAST) | Phase 1 | withdrawn | Jun 9, 2021 | Oncopeptides AB | Sponsor made the decision to terminate the COAST study to refocus the OPD5 clinical program. | Other (stated, no rule matched) |
| NCT00256776 | MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous… | Phase 3 | terminated | Nov 22, 2005 | European Society for Blood and Marrow Transplantation | not stated | Not stated |
| NCT03537222 | Quality of Life in Patients With Multiple Myeloma-validation Study | — | terminated | May 25, 2018 | Zurich University of Applied Sciences | Not enough participants and study funding | Funding |
| NCT02840110 | Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product | — | terminated | Jul 21, 2016 | Cogent Biosciences, Inc. | Business Decision | Sponsor / business decision |
| NCT02576977 | Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475)… | Phase 3 | terminated | Oct 15, 2015 | Merck Sharp & Dohme LLC | The study was terminated early due to business reasons | Sponsor / business decision |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem… | Phase 1 | withdrawn | Jul 9, 2020 | Medigene AG | Medigene transfered all rights to a new Sponsor | Other (stated, no rule matched) |
| NCT02394210 | Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma(EPA-MMBR) | — | terminated | Mar 20, 2015 | Celgene | Bias in the study | Other (stated, no rule matched) |
| NCT01045382 | MSC and HSC Coinfusion in Mismatched Minitransplants | Phase 2 | terminated | Jan 11, 2010 | University of Liege | recruitment too slow | Enrollment / accrual |
| NCT04584307 | Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second…(Immuno-POWER) | Phase 2 | withdrawn | Oct 12, 2020 | Natalie Callendar | Funder pulled support/funding | Funding |
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | Phase 1 | terminated | Aug 13, 2012 | Gilead Sciences | PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD… | Safety / toxicity |
| NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With… | Phase 1 / Phase 2 | terminated | Apr 12, 2010 | Gilead Sciences | Study was terminated due to lack of efficacy | Efficacy / futility |
| NCT03618212 | MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the…(MYMO) | — | terminated | Aug 7, 2018 | Centre Hospitalier Universitaire de Nīmes | Departure of the project leader | Other (stated, no rule matched) |
| NCT04730505 | A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple…(MyHOPE™) | Phase 1 | terminated | Jan 29, 2021 | Celgene | Study faced multiple challenges and its launch was heavily impacted by COVID, which in turn has… | COVID-19 / pandemic |
| NCT03634800 | Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)(RISE-M) | Phase 2 | terminated | Aug 16, 2018 | Weill Medical College of Cornell University | Lack of patient accruals. | Enrollment / accrual |
| NCT01946152 | Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | Sep 19, 2013 | M.D. Anderson Cancer Center | Per PI at time of CR | Other (stated, no rule matched) |
| NCT04178902 | A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With… | Phase 1 | terminated | Nov 26, 2019 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02579863 | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in… | Phase 3 | terminated | Oct 20, 2015 | Merck Sharp & Dohme LLC | The study was terminated early due to business reasons | Sponsor / business decision |
| NCT00445068 | Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma | Phase 2 | terminated | Mar 8, 2007 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT04288765 | Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in… | Phase 3 | withdrawn | Feb 28, 2020 | Grupo Cooperativo de Hemopatías Malignas | incomplete recruitment | Enrollment / accrual |
| NCT03567616 | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants… | Phase 2 | terminated | Jun 26, 2018 | AbbVie | Following results of the primary progression-free survival analysis from Study NCT02755597,… | Sponsor / business decision |
| NCT02128230 | UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete… | Phase 2 | terminated | May 1, 2014 | University of Arkansas | Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program. | Efficacy / futility |
| NCT02757326 | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma(ABC-103) | Phase 1 / Phase 2 | terminated | May 2, 2016 | RedHill Biopharma Limited | Expiration of National Cancer Institute (NCI) funding of the study. | Funding |
| NCT03687125 | Tinostamustine Conditioning and Autologous Stem Cell(TITANIUM1) | Phase 1 / Phase 2 | terminated | Sep 27, 2018 | Mundipharma-EDO GmbH | Sponsor decision based on adverse events limiting administration of higher doses required to… | Safety / toxicity |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host… | Phase 2 / Phase 3 | terminated | Aug 27, 2009 | Kiadis Pharma | not stated | Not stated |
| NCT03520985 | Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma(OptiPOM) | Phase 2 | terminated | May 11, 2018 | Swiss Cancer Institute | Feasibility (low patient accrual and financial reasons) | Enrollment / accrual |
| NCT00003511 | Antineoplaston Therapy in Treating Patients With Multiple Myeloma | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT03910439 | Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed… | Phase 2 | terminated | Apr 10, 2019 | National Cancer Institute (NCI) | Slow/Insufficient accrual/COVID-19 pandemic | COVID-19 / pandemic |
| NCT01999335 | A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory… | Phase 1 | terminated | Dec 3, 2013 | Amgen | A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of… | Safety / toxicity |
| NCT01079429 | Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma…(GENOMGUS) | — | terminated | Mar 3, 2010 | Rennes University Hospital | sponsor and investigator 's decision | Investigator |
| NCT02036502 | A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in… | Phase 1 | terminated | Jan 15, 2014 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT03340883 | Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple… | Phase 1 / Phase 2 | terminated | Nov 14, 2017 | Chinook Therapeutics, Inc. | No objective responses observed following completion of Phase 1 dose-escalation | Other (stated, no rule matched) |
| NCT03440411 | Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During…(PO-3887) | Phase 3 | terminated | Feb 22, 2018 | Fondazione EMN Italy Onlus | Low enrollment | Enrollment / accrual |
| NCT01109407 | Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and… | — | terminated | Apr 23, 2010 | National Cancer Institute (NCI) | PI Left before primary outcome was established | Investigator |
| NCT00437034 | Aflibercept for Relapsed Multiple Myeloma | Phase 2 | terminated | Feb 19, 2007 | National Cancer Institute (NCI) | Poor accrual | Enrollment / accrual |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | N/A | terminated | Sep 15, 2005 | Masonic Cancer Center, University of Minnesota | replaced by another study ; Trial re-written as MT2015-29 | Other (stated, no rule matched) |
| NCT03512353 | A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple… | Phase 2 | terminated | Apr 30, 2018 | Amgen | Sponsor Decision | Sponsor / business decision |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic… | Phase 1 | terminated | Jul 18, 2012 | Barbara Ann Karmanos Cancer Institute | Study terminated due to slow accrual. | Enrollment / accrual |
| NCT01121120 | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell…(TXA127-PBSC) | Phase 2 | terminated | May 12, 2010 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT03117361 | Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in… | Phase 2 | terminated | Apr 17, 2017 | PharmaMar | PharmaMar has decided to end this study due to the slow recruitment rate of the trial | Enrollment / accrual |
| NCT02897830 | Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus…(IFM2014-03) | Phase 2 | terminated | Sep 13, 2016 | University Hospital, Toulouse | negatives results | Other (stated, no rule matched) |
| NCT04621955 | Observational Study of Home Administration of Carfilzomib(KARE-2) | — | withdrawn | Nov 9, 2020 | Universitaire Ziekenhuizen KU Leuven | Not possible to conduct study | Other (stated, no rule matched) |
| NCT03033316 | A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in…(AMETHYST) | Phase 1 / Phase 2 | terminated | Jan 26, 2017 | Enceladus Pharmaceuticals BV | Patient enrolment issues | Enrollment / accrual |
| NCT03287804 | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma(APRIL) | Phase 1 / Phase 2 | terminated | Sep 19, 2017 | Autolus Limited | Preliminary efficacy seen to date following treatment with AUTO2 has been determined not sufficient… | Efficacy / futility |
| NCT03779555 | Lenalidomide Adherence in Older Adults | — | terminated | Dec 19, 2018 | Washington University School of Medicine | Principal Investigator left the university | Investigator |
| NCT03963024 | Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT(TrRaMM-TMI) | Phase 1 | terminated | May 24, 2019 | IRCCS San Raffaele | low rate of enrolment | Enrollment / accrual |
| NCT02786485 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After… | Phase 1 | withdrawn | Jun 1, 2016 | Bellicum Pharmaceuticals | not stated | Not stated |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jan 24, 2022source: clinicaltrials